Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS
NCT02190149 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64
Last updated 2021-03-17
Summary
This 6-month prospective outcomes study addresses the association between timing of infusion, patient activity levels, and bleeding episodes through patient-reported measurements.
Conditions
- Hemophilia A
- Hemophilia B
Interventions
- BIOLOGICAL
-
ADVATE (Antihemophilic Factor [Recombinant])
- BIOLOGICAL
-
RIXUBIS (Coagulation Factor IX [Recombinant])
Sponsors & Collaborators
-
Baxalta now part of Shire
lead INDUSTRY
Principal Investigators
-
Study Director · Takeda
Eligibility
- Min Age
- 13 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-07-22
- Primary Completion
- 2016-03-29
- Completion
- 2016-03-29
Countries
- United States
Study Locations
More Related Trials
-
Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A
NCT00038935 ·Status: COMPLETED ·Phase: PHASE3
-
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
NCT05022459 ·Status: RECRUITING
-
A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
NCT01496274 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
NCT02053792 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
NCT02035384 ·Status: COMPLETED
-
Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A
NCT00141843 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B
NCT01361126 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
NCT00168051 ·Status: WITHDRAWN ·Phase: PHASE4
-
Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
NCT02634723 ·Status: COMPLETED
-
Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00243386 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
NCT01561391 ·Status: COMPLETED ·Phase: PHASE4
-
Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants
NCT03876301 ·Status: COMPLETED
-
Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
NCT00243659 ·Status: COMPLETED ·Phase: PHASE3
-
Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens
NCT02314325 ·Status: UNKNOWN ·Phase: PHASE4
-
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
NCT04083781 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A
NCT01181128 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101
NCT00189982 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
NCT04690322 ·Status: WITHDRAWN ·Phase: PHASE4
-
Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901
NCT00157053 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
NCT05568719 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A
NCT03061201 ·Status: COMPLETED ·Phase: PHASE2
-
Factor IX as Adjunctive Therapy to Emicizumab (EMIX)
NCT05281718 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors
NCT02020369 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors
NCT04684940 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A
NCT00782470 ·Status: COMPLETED